T0	Participants 116 153	sentinel lymph node-positive patients
T1	Participants 446 527	patients with sentinel lymph node-positive (SLN+) primary invasive breast cancer.
T2	Participants 884 917	patients with SLN+ breast cancer.
T3	Participants 939 979	Patients with SLN+ primary breast cancer
T4	Participants 1287 1304	474 SLN+ patients
T5	Participants 1529 1565	patients were premenopausal (34% vs.
T6	Participants 1566 1601	27%; P = .095) and had pT2-3 tumors
T7	Participants 1722 1811	patients with known human epidermal growth factor receptor type 2 positive tumor (12% vs.
T8	Participants 1812 1826	17%, P = .066)
T9	Participants 2359 2422	premenopausal patients and patients with larger (pT2-3) tumors.